Global Blood Therapeutics - GBT Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00%
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$68.49 As of 11/2/2022 01:00 AM ET

+0 (0.00%)

Get New Global Blood Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBT

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $68.49.

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Global Blood Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/3/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/1/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/2/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/31/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/29/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/27/2024

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/27/2024

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/26/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/21/2022	Cantor Fitzgerald	Reiterated Rating	Neutral		Low
8/15/2022	Guggenheim	Boost Target		$72.00	N/A
8/15/2022	Wedbush	Downgrade	Neutral		N/A
8/15/2022	Truist Financial	Downgrade	Hold		N/A
8/15/2022	Oppenheimer	Downgrade	Market Perform		N/A
8/9/2022	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral		Low
8/9/2022	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$68.50	Low
8/9/2022	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$66.00 ➝ $68.50	Low
8/9/2022	Cowen	Downgrade	Market Perform	$67.00 ➝ $68.50	Low
8/8/2022	Wedbush	Reiterated Rating	Outperform ➝ Neutral		Low
8/8/2022	Stifel Nicolaus	Reiterated Rating	Buy ➝ Hold		Low
8/8/2022	William Blair	Downgrade	Outperform ➝ Market Perform		Low
8/8/2022	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$40.00 ➝ $72.00	Low
6/28/2022	JPMorgan Chase & Co.	Lower Target	Neutral	$39.00 ➝ $36.00	Low
6/20/2022	Wedbush	Set Target		$74.00	Low
5/5/2022	Oppenheimer	Lower Target		$86.00 ➝ $71.00	High
4/28/2022	Cantor Fitzgerald	Initiated Coverage	Buy	$75.00	High
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
3/28/2022	Wedbush	Reiterated Rating	Outperform		High
2/28/2022	Morgan Stanley	Boost Target	Equal Weight	$28.00 ➝ $31.00	Medium
2/24/2022	HC Wainwright	Reiterated Rating	Buy	$75.00	High
2/24/2022	Cowen	Lower Target		$72.00 ➝ $67.00	High
2/24/2022	Oppenheimer	Lower Target	Outperform	$92.00 ➝ $86.00	High
12/21/2021	SVB Leerink	Lower Target	Outperform	$56.00 ➝ $53.00	Low
12/14/2021	SVB Leerink	Boost Target	Outperform	$54.00 ➝ $56.00	High
12/7/2021	William Blair	Upgrade	Market Perform ➝ Outperform		High
11/5/2021	Royal Bank of Canada	Lower Target	Outperform	$66.00 ➝ $64.00	High
10/6/2021	Jefferies Financial Group	Initiated Coverage	Buy	$68.00	High
9/8/2021	Wedbush	Reiterated Rating	Buy		Low
8/4/2021	Truist Financial	Upgrade	Buy	$45.00 ➝ $50.00	High
8/4/2021	Piper Sandler	Lower Target	Neutral	$45.00 ➝ $40.00	High
6/28/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$70.00 ➝ $36.00	High
5/7/2021	Cantor Fitzgerald	Lower Target	Overweight	$120.00 ➝ $110.00	Low
5/6/2021	Piper Sandler	Lower Target		$50.00 ➝ $45.00	High
5/6/2021	Roth Capital	Lower Target	Buy	$128.00 ➝ $124.00	High
4/14/2021	SVB Leerink	Initiated Coverage	Outperform	$54.00	Low
3/11/2021	Wolfe Research	Initiated Coverage	Outperform	$67.00	Low
2/25/2021	William Blair	Downgrade	Outperform ➝ Market Perform		High
1/20/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$75.00 ➝ $50.00	Low
12/16/2020	Morgan Stanley	Lower Target	Equal Weight	$67.00 ➝ $45.00	Low
12/15/2020	HC Wainwright	Reiterated Rating	Buy	$75.00	Low
12/8/2020	William Blair	Reiterated Rating	Buy		Medium
12/3/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$75.00	High
11/18/2020	Cantor Fitzgerald	Lower Target	Overweight	$133.00 ➝ $120.00	Low
11/9/2020	Truist Financial	Lower Target		$78.00 ➝ $55.00	Low
11/6/2020	Morgan Stanley	Lower Target	Equal Weight	$68.00 ➝ $67.00	High
11/6/2020	Roth Capital	Lower Target	Buy	$131.00 ➝ $128.00	High
11/6/2020	Stifel Nicolaus	Lower Target	Buy	$120.00 ➝ $101.00	High
11/6/2020	Piper Sandler	Boost Target	Overweight	$75.00 ➝ $120.00	High
11/6/2020	Oppenheimer	Lower Target	Outperform	$102.00 ➝ $92.00	High
11/6/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		High
10/13/2020	Morgan Stanley	Lower Target	Equal Weight	$75.00 ➝ $68.00	High
10/6/2020	Evercore ISI	Initiated Coverage	Outperform	$102.00	Medium
8/25/2020	Wedbush	Boost Target		$145.00 ➝ $152.00	Medium
8/24/2020	Raymond James	Initiated Coverage	Outperform	$115.00	Medium
8/6/2020	HC Wainwright	Reiterated Rating	Buy	$150.00	Low
8/6/2020	Stifel Nicolaus	Boost Target	Buy	$113.00 ➝ $118.00	High
7/29/2020	Piper Sandler	Reiterated Rating	Buy	$120.00	Low
7/20/2020	Roth Capital	Initiated Coverage	Buy	$129.00	Low
7/13/2020	Bank of America	Initiated Coverage	Buy	$92.00	High
7/1/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$91.00 ➝ $103.00	High
6/25/2020	HC Wainwright	Reiterated Rating	Buy	$150.00	Low
6/23/2020	Wedbush	Reiterated Rating	Buy	$145.00	High
6/15/2020	Oppenheimer	Reiterated Rating	Buy	$101.00	High
6/12/2020	Wells Fargo & Company	Reiterated Rating	Buy		High
5/12/2020	Wedbush	Reiterated Rating	Buy	$145.00	Low
5/7/2020	Cantor Fitzgerald	Boost Target		$105.00 ➝ $130.00	Low
5/7/2020	Nomura	Reiterated Rating	Buy	$112.00	Low
5/7/2020	Wells Fargo & Company	Boost Target	Overweight	$122.00 ➝ $133.00	Medium
5/7/2020	Oppenheimer	Boost Target	Outperform	$88.00 ➝ $101.00	Low
5/7/2020	Morgan Stanley	Boost Target	Equal Weight	$70.00 ➝ $75.00	High
4/27/2020	Stifel Nicolaus	Initiated Coverage	Buy	$112.00	Low
4/15/2020	Morgan Stanley	Lower Target	Equal Weight	$71.00 ➝ $70.00	Low
3/19/2020	Wedbush	Reiterated Rating	Buy	$145.00	Medium
3/18/2020	Oppenheimer	Lower Target		$100.00 ➝ $88.00	Low
3/3/2020	Morgan Stanley	Lower Target	Equal Weight	$80.00 ➝ $71.00	High
1/31/2020	SunTrust Banks	Downgrade	Buy ➝ Hold	$110.00 ➝ $75.00	High
1/17/2020	Morgan Stanley	Boost Target	Equal Weight	$79.00 ➝ $80.00	Medium
12/23/2019	Piper Sandler Companies	Reiterated Rating	Buy	$120.00	N/A
12/22/2019	Wedbush	Reiterated Rating	Buy	$143.00	Medium
12/18/2019	William Blair	Reiterated Rating	Buy		High
12/17/2019	JPMorgan Chase & Co.	Boost Target	Equal Weight	$58.00 ➝ $79.00	Low
12/10/2019	Piper Sandler Companies	Boost Target		$95.00 ➝ $120.00	High
12/9/2019	Oppenheimer	Reiterated Rating	Buy	$100.00	Low
11/26/2019	Nomura Securities	Boost Target	Buy	$109.00 ➝ $112.00	High
11/26/2019	Wedbush	Reiterated Rating	Buy	$143.00	High
11/26/2019	Janney Montgomery Scott	Boost Target	Buy	$75.00 ➝ $90.00	High
11/26/2019	SunTrust Banks	Boost Target	Buy	$110.00	High
11/26/2019	Piper Sandler Companies	Boost Target	Overweight	$80.00 ➝ $95.00	High
11/25/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$110.00 ➝ $98.00	High
10/17/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		High
10/14/2019	SunTrust Banks	Boost Target	Buy	$100.00	Low
10/9/2019	Cowen	Set Target	Buy	$83.00	Low
10/9/2019	Wedbush	Reiterated Rating	Buy	$120.00	Low
10/9/2019	Wells Fargo & Company	Boost Target	Outperform	$96.00 ➝ $104.00	Medium
10/9/2019	HC Wainwright	Reiterated Rating	Buy	$150.00	Medium
10/8/2019	William Blair	Reiterated Rating	Buy		Low
9/12/2019	Wedbush	Reiterated Rating	Buy	$120.00	Medium
9/6/2019	HC Wainwright	Set Target	Buy	$150.00	Low
9/5/2019	Cowen	Set Target	Buy	$83.00	Low
9/5/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
9/5/2019	Wedbush	Boost Target	Outperform ➝ Hold	$103.00 ➝ $120.00	High
8/12/2019	Wedbush	Reiterated Rating	Outperform	$103.00	Low
8/11/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Low
8/9/2019	Morgan Stanley	Set Target	Hold	$60.00	Medium
8/8/2019	Cowen	Reiterated Rating	Buy	$83.00	Low
8/8/2019	HC Wainwright	Reiterated Rating	Buy	$150.00	Low
6/28/2019	Wedbush	Set Target	Buy	$103.00	Medium
6/25/2019	HC Wainwright	Reiterated Rating	Buy		Low
6/17/2019	Wedbush	Reiterated Rating	Buy	$107.00	Medium
6/16/2019	Cowen	Reiterated Rating	Buy		Medium
6/14/2019	Cantor Fitzgerald	Set Target	Buy	$96.00 ➝ $110.00	High
6/11/2019	Wedbush	Reiterated Rating	Buy	$107.00	Low
6/3/2019	Wedbush	Reiterated Rating	Buy	$95.00 ➝ $107.00	High
5/29/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$75.00	Low
5/13/2019	Wedbush	Reiterated Rating	Buy	$95.00	High
5/9/2019	Oppenheimer	Boost Target	Outperform	$82.00 ➝ $89.00	Medium

(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/29/2023

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/29/2023

0 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/28/2023

0 very positive mentions
0 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/28/2023

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/27/2024

1 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/26/2024

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/27/2024

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/26/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

No positive mentions tracked during this time.

Very Positive

No very positive mentions tracked during this time.

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Today's Range

Now: $68.49

$68.49

50 Day Range

MA: $68.47

$68.07

$68.49

52 Week Range

Now: $68.49

$21.65

$73.02

Volume

74 shs

Average Volume

2,065,836 shs

Market Capitalization

$4.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?: The following sell-side analysts have issued reports on Global Blood Therapeutics in the last twelve months: StockNews.com.
View the latest analyst ratings for GBT.
What is the current price target for Global Blood Therapeutics?: 0 Wall Street analysts have set twelve-month price targets for Global Blood Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Global Blood Therapeutics in the next year.
View the latest price targets for GBT.
What is the current consensus analyst rating for Global Blood Therapeutics?: Global Blood Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GBT.
What other companies compete with Global Blood Therapeutics?: Other companies that are similar to Global Blood Therapeutics include Organon & Co., BridgeBio Pharma, Madrigal Pharmaceuticals, Nuvalent and Alpine Immune Sciences. Learn More about companies similar to Global Blood Therapeutics.
How do I contact Global Blood Therapeutics' investor relations team?: Global Blood Therapeutics' physical mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 741-7700 and its investor relations email address is [email protected]. The official website for Global Blood Therapeutics is www.gbt.com. Learn More about contacing Global Blood Therapeutics investor relations.

Global Blood Therapeutics - GBT Stock Price Target and Predictions

Analyst Price Target for GBT

Current Consensus is N/A

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?

What is the current price target for Global Blood Therapeutics?

What is the current consensus analyst rating for Global Blood Therapeutics?

What other companies compete with Global Blood Therapeutics?

How do I contact Global Blood Therapeutics' investor relations team?